Skip to main content
. 2015 Jun 4;2015:269641. doi: 10.1155/2015/269641

Figure 1.

Figure 1

Iron oxide nanoparticles as lymphotropic agent. Normal portion of lymph node darkens after infusion of iron oxide nanoparticle while metastatic portion of the node does not darken (white arrow; (a) before and (b) after iron oxide nanoparticle administration). Corresponding sectioned lymph node showing metastasis marked by arrow and the normal portion marked by arrowheads (c). Reprinted with permission from [9].